We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Maelor | LSE:MLR | London | Ordinary Share | GB00B2QBY649 | ORD 70P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 100.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
RNS Number:4238Y Maelor PLC 15 February 2006 15 February 2006 Maelor plc The Directors of Maelor note the recent rise in the Company's share price and are not aware of any specific external events that may have caused the rise. During the week, the Company achieved the return in-house of Volplex, Maelor's treatment for hypovolaemia, enabling the Company to focus directly on increasing sales and market share. Despite the de-stocking process involved in returning Volplex from a distributor, Company turnover for the second half of the year is anticipated to be in line with the levels seen in the first six months. Operating losses are likely to half in the final six months of the year relative to the first six months, ahead of expectations. The Directors are pleased with the progress of the recently announced strategic review, which they expect to complete on schedule and be in a position to update the market in parallel with year end results. Further information: Tim Wright, CEO Maelor plc 01978 810 153 Ben Atwell, Financial Dynamics 020 7831 3113 This information is provided by RNS The company news service from the London Stock Exchange END SPMEAPALFESKEFE
1 Year Maelor Chart |
1 Month Maelor Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions